PMID- 34796969
OWN - NLM
STAT- MEDLINE
DCOM- 20220504
LR  - 20220504
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 237
IP  - 2
DP  - 2022 Feb
TI  - Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment 
      for optimal cancer immunotherapy.
PG  - 1285-1298
LID - 10.1002/jcp.30643 [doi]
AB  - The development of new strategies of anticancer immunotherapies has provided 
      promising approaches in the treatment of solid tumors. However, despite the 
      improved survival in responders, most of the patients show incomplete responses 
      with a lack of remarkable clinical improvement. Hypoxia has been identified as a 
      common characteristic of solid tumors contributing to different aspects of tumor 
      progression, including invasion, metastasis, and the creation of the 
      immunosuppressive tumor microenvironment. Hypoxia, through its main mediator, 
      hypoxia-inducible factor-1 (HIF-1) is also associated with the limited efficacy 
      of immunotherapies. Therefore, designing new strategies for immunotherapy 
      implicating therapeutic targeting of HIF-1 molecules may enhance the clinical 
      effectiveness of immunotherapy. Here, we discuss the contribution of hypoxia to 
      the development of the immunosuppressive tumor microenvironment. We will also 
      outline different strategies for targeting hypoxia to provide insight into the 
      therapeutic potential of the application of such strategies to improve the 
      clinical benefit of cancer immunotherapy.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Kheshtchin, Nasim
AU  - Kheshtchin N
AUID- ORCID: 0000-0002-9963-2256
AD  - Department of Immunology, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
AD  - Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Hadjati, Jamshid
AU  - Hadjati J
AUID- ORCID: 0000-0002-8747-123X
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20211119
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
SB  - IM
MH  - Cell Hypoxia
MH  - Humans
MH  - Hypoxia
MH  - Hypoxia-Inducible Factor 1
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/genetics
MH  - Immunotherapy
MH  - *Neoplasms/pathology/therapy
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - HIF inhibitors
OT  - HIF-1alpha
OT  - hypoxia
OT  - immunotherapy
OT  - tumor microenvironment
EDAT- 2021/11/20 06:00
MHDA- 2022/05/06 06:00
CRDT- 2021/11/19 08:47
PHST- 2021/11/03 00:00 [revised]
PHST- 2021/07/05 00:00 [received]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/11/20 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2021/11/19 08:47 [entrez]
AID - 10.1002/jcp.30643 [doi]
PST - ppublish
SO  - J Cell Physiol. 2022 Feb;237(2):1285-1298. doi: 10.1002/jcp.30643. Epub 2021 Nov 
      19.